Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Recruiting now · Phase 2

Conditions studied: Schizophrenia

In brief

The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by positive and negative syndrome scale (PANSS) total score in participants with schizophrenia.

Key facts

Study ID

NCT07680946

Run by

TG Therapeutics, Inc.

People needed

60

Starts

2026-07-03

Expected to finish

2029-03-01

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary diagnosis of schizophrenia.
• Treatment-resistant.
• Requires antipsychotic treatment and is currently receiving "standard of care".
• PANSS total score between 80 and 120, inclusive at screening and baseline.

You may not qualify if…

• Any primary Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) disorder other than schizophrenia.
• Ongoing clozapine treatment.
• Risk for suicidal behavior.
• Any severe or uncontrolled medical condition that could affect the participant's ability to participate.
• Note: Other protocol-specified Inclusion/Exclusion criteria may apply

Where it is running

• TG Therapeutics Investigational Trial Site — Little Rock, Arkansas, United States (enrolling)
• TG Therapeutics Investigational Trial Site — Richardson, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.